Breaking News, Promotions & Moves

Biothera Names Biomarker Development VP

Maimonis to lead development and commercialization of assays for Phase III cancer drug

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Peter J. Maimonis, Ph.D. has been appointed vice president of biomarker development at Biothera and will lead the development and commercialization of assays for the company’s Phase III cancer immunotherapy, Imprime PGG. Dr. Maimonis previously held senior positions with various pharmaceutical and diagnostic companies, including senior director, Cancer Cell Biology at On-Q-ity, vice president of Biology R&D at Decision Biomarkers, and associate director for Oncology Research at Bayer Health ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters